Abstract
Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Current Pharmaceutical Design
Title:Heregulin in Breast Cancer: Old Story, New Paradigm
Volume: 20 Issue: 30
Author(s): Ashwani Khurana, Anatilde Gonzalez-Guerrico and Ruth Lupu
Affiliation:
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Abstract: Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Export Options
About this article
Cite this article as:
Khurana Ashwani, Gonzalez-Guerrico Anatilde and Lupu Ruth, Heregulin in Breast Cancer: Old Story, New Paradigm, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131125151519
DOI https://dx.doi.org/10.2174/1381612819666131125151519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oncologists Current Opinion on the Treatment of Colon Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents β-Galactosidase and Galactooligosaccharides Production and Applications
Recent Patents on Chemical Engineering Glycosidated Phospholipids – a Promising Group of Anti-Tumour Lipids
Anti-Cancer Agents in Medicinal Chemistry In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry In Vivo Transdermal Delivery of Leuprolide Using Microneedles and Iontophoresis
Current Pharmaceutical Biotechnology Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Downstream Processing for Production of Value Added Products from Coconut
Current Biochemical Engineering (Discontinued) Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design